Nexturastat A Liposomes
1195 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 1142 - DLL-0012-1D-5MG
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 5 mg
Parameters
| Additional information | 292 mM sucrose, 0.5% DPBS (1X) |
|---|
DLL-0012-1A-1MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
595 €
DLL-0012-1A-5MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
995 €
DLL-0012-1B-1MG
Nexturastat A Liposomes
PEGylated liposomes containing Nexturastat A. Nexturastat A is a potent and selective HDAC6 inhibitor (IC50: 5 nM), with >190-fold selectivity over other HDACs. This product is a pre-formulated liposomal version of Nexturastat A which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
795 €
PN-0004-2ML
DMPC Liposomes
Pure DMPC liposomes, 30 mM, extruded and supplied sterile-filtered in glass vial.We synthesize custom liposomes like this. To see a full list of our formulation capabilities, click here.Or, contact us today to request a custom formulation.
450 €
DLL-0021-1A-10ML
Gilteritinib (ASP2215) Liposomes
Gilteritinib (ASP2215) is a small-molecule inhibitor of FLT3/AXL with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. Gilteritinib (ASP2215) is a highly selective FLT3 inhibitor that demonstrates activity against both FLT3-ITD and FLT3-TKD mutation subtypes and selectively inhibits FLT3 at concentrations roughly 800-fold lower than those required to inhibit c-Kit (230 nM). This product is a pre-formulated liposomal version of Gilteritinib (ASP2215) which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance; the lipid composition of the liposomes is the same as Doxil. For preclinical research use only.
4095 €
DLL-0021-1A-2ML
Gilteritinib (ASP2215) Liposomes
Gilteritinib (ASP2215) is a small-molecule inhibitor of FLT3/AXL with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. Gilteritinib (ASP2215) is a highly selective FLT3 inhibitor that demonstrates activity against both FLT3-ITD and FLT3-TKD mutation subtypes and selectively inhibits FLT3 at concentrations roughly 800-fold lower than those required to inhibit c-Kit (230 nM). This product is a pre-formulated liposomal version of Gilteritinib (ASP2215) which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance; the lipid composition of the liposomes is the same as Doxil. For preclinical research use only.
995 €
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Biologiska läkemedel – Modernitet inom farmaci
1 August 2025
By: Author , 2 Comment
Icke-steroida antiinflammatoriska läkemedel – viktig information om populära läkemedel
22 July 2025